News

Tempus partners with Verastem for companion diagnostic development
Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...
PharmExec13d
FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...
Seeking Alpha3d
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...
PMLive11d
FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type
The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...
Nasdaq9d
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Advanced Solid Tumors To supplement Verastem Oncology’s condensed consolidated financial statements, which are prepared and presented in ...
Verastem: Q1 Earnings Snapshot
The Needham, Massachusetts-based company said it had a loss of 96 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
Houston Chronicle10d
Verastem: Q1 Earnings Snapshot
NEEDHAM, Mass. (AP) — NEEDHAM, Mass. (AP) — Verastem Inc. (VSTM) on Tuesday reported a loss of $52.1 million in its first quarter. The Needham, Massachusetts-based company said it had a loss ...